Please assess the completion status of the following clinical trial:

Trial Title: ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 12 years and ≥ 40 kg~2. Documented laboratory diagnosis of infection with HIV-1 (positive enzyme-linked immunosorbent assay HIV-1 antibody test) at screening~3. Plasma HIV-1 RNA (VL) ≥ 500 copies/mL~4. All pre-existing medical or laboratory abnormalities must be deemed to be stable by the investigator prior to study enrolment~5. Calculated creatinine clearance (CrCl) \> 60 mL/min (Cockcroft-Gault formula) in \> 18 years old OR \> 80 mL/min (modified Cockcroft-Gault) in ≤ 18 years old~6. Ability to comprehend the full nature and purpose of the study, in the opinion of the investigator, and to comply with the requirements of the entire study.~To enrol in extension post-96 weeks:~Each patient must meet all of the following criteria to be enrolled in this study:~1. Previously enrolled on the ADVANCE study, and followed to week 96 (including those on post-trial access)~2. Ability to comprehend the full nature and purpose of the study, including the extended timeline, in the opinion of the investigator, and to comply with the requirements of the entire study.~Exclusion Criteria:~1. Previously received more than 30 days of treatment with any form of antiretroviral therapy (ART) or~2. Received any antiretrovirals within the last 6 months~3. Women who are pregnant at the time of the screening or baseline visit~4. Active tuberculosis and/or are on antituberculous therapy at the time of the baseline visit~5. Taking and cannot discontinue prohibited concomitant medications listed in 7.3 at least 2 weeks prior to the baseline visit and for the duration of the study period~6. Clinically unstable, in the investigator's opinion~7. Current history of drug or alcohol abuse that, in the opinion of the investigator, may be an impediment to patient adherence to the protocol~8. Patients who participated in a study with an investigational drug within 60 days of screening or who are currently receiving treatment with any other investigational drug or device may be ineligible to participate. This is an investigator decision~9. Have a strong likelihood of relocating far enough to make access to the study site difficult~10. History or presence of allergy to the study drugs or their components~11. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones); Child-Pugh C.~To enrol in extension post-96 weeks:~Patients meeting the following criteria will be excluded from the study:~1. HbA1c, lipids and blood pressures that are not responding to treatment, in the opinion of the investigator and in consultation with the principal investigator, justifying substitution of DTG or TAF~2. Clinically unstable, in the opinion of the investigator~3. Have a strong likelihood of relocating far enough to make access to the study site difficult.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenofovir Alafenamide (Type: ACTIVE_COMPARATOR): Descovy: Tenofivir alafenamide tablets 25mg daily, Emtricitabine 200mg daily
- Dolutegravir (Type: ACTIVE_COMPARATOR): Dolutegravir 50mg daily, Truvada 500mg daily
- Atripla (Type: ACTIVE_COMPARATOR): Atripla: Efavirenz 600mg daily, Tenofovir Disoproxil Fumarate 300mg daily, Emtricitabine 200mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).